MEI Pharma (MEIP) Insider Trading & Ownership $2.60 -0.05 (-1.70%) Closing price 02/21/2025 03:50 PM EasternExtended Trading$2.75 +0.14 (+5.53%) As of 02/21/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends MEI Pharma (NASDAQ:MEIP) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage3.12%Number OfInsiders Buying(Last 3 Years)2Amount OfInsider Buying(Last 3 Years)$1.07 MNumber OfInsiders Selling(Last 3 Years)0 Get MEIP Insider Trade Alerts Want to know when executives and insiders are buying or selling MEI Pharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address MEIP Insider Buying and Selling by Quarter MEI Pharma Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails9/22/2023Anson Funds Management LpMajor ShareholderBuy48,060$6.85$329,211.00 9/20/2023Anson Funds Management LpMajor ShareholderBuy120,000$6.01$721,200.00 2/28/2023Charles V Baltic IIIDirectorBuy4,075$4.60$18,745.00 (Data available from 1/1/2013 forward) MEIP Insider Trading Activity - Frequently Asked Questions Who is on MEI Pharma's Insider Roster? The list of insiders at MEI Pharma includes Anson Funds Management Lp, and Charles V Baltic III. Learn more on insiders at MEIP. What percentage of MEI Pharma stock is owned by insiders? 3.12% of MEI Pharma stock is owned by insiders. Learn more on MEIP's insider holdings. Which MEI Pharma insiders have been buying company stock? The following insiders have purchased MEIP shares in the last 24 months: Anson Funds Management Lp ($1,050,411.00), and Charles V Baltic III ($18,745.00). How much insider buying is happening at MEI Pharma? Insiders have purchased a total of 172,135 MEIP shares in the last 24 months for a total of $1,069,156.00 bought. MEI Pharma Key ExecutivesMr. David M. Urso B.A. (Age 60)Esq., J.D., CEO, President & Director Compensation: $748.46kDr. Richard G. Ghalie M.D. (Age 66)MBA, Chief Medical Officer Compensation: $627.76kMr. Justin J. File (Age 54)CFO & Corporate Secretary Ms. Yomara Gomez-NaidenSenior Vice President of Operations & QualityMs. Nicole Chyoko IidaVice President of Legal AffairsMs. Anne FreseChief People OfficerDr. Robert D. Mass (Age 70)Strategic Advisor Compensation: $201.68kMr. David A. Walsey J.D.L.L.M., Senior Vice President of Corporate Affairs More Insider Trading Tools from MarketBeat Related Companies Aerovate Therapeutics Insider Selling bluebird bio Insider Selling FitLife Brands Insider Selling vTv Therapeutics Insider Selling 23andMe Insider Selling Werewolf Therapeutics Insider Selling Century Therapeutics Insider Selling Aadi Bioscience Insider Selling Shattuck Labs Insider Selling CytomX Therapeutics Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles 3 Stocks With Robust Growth Outlooks Insiders Are BuyingMETA Stock: Insider Selling Ramps Up—What It Means for InvestorsThese Are the Dividend Stocks Insiders Bought in JanuaryInsider Selling in Tech Stocks Spikes in Q43 Small-Cap Stocks Insiders and Institutions Are Buying This page (NASDAQ:MEIP) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendThere's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a tra...Investors Alley | Sponsored2025 AI Blueprint features Nvidia’s march to $5 trillionNvidia is now one of the most valuable companies in the world. It currently ranks second, just behind Apple...Weiss Ratings | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 financial crisis over a year in advance. His readers had a chance to lock in g...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MEI Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MEI Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
